Stopping Wegovy and Gaining Weight Back: What Actually Happens

Step 1: understanding why the weight comes back

Wegovy does not fix the underlying biology of obesity, it modulates it. GLP-1 receptor agonists like semaglutide reduce appetite, slow gastric emptying and influence how the brain processes hunger signals. While you are taking the medicine, those effects are present every week. When you stop, they are not.

In the STEP 1 extension study, participants who had lost around 17% of their body weight during 68 weeks of treatment and then switched to placebo for a further 52 weeks regained, on average, about 11.6 percentage points of that loss. That brought their net weight change back to roughly 5% below their starting point, a partial but meaningful reversal. The biology involved is not unusual. Appetite hormones, including ghrelin, tend to increase after significant weight loss regardless of how that loss was achieved, and body weight has a physiological set-point that resists change once the medicine is removed.

Framing this clearly matters: weight regain after stopping does not mean the treatment failed, it means obesity is a chronic condition, in the same way that blood pressure climbs again if antihypertensive medication is stopped. The NICE appraisal of Wegovy (NICE TA875) notes a maximum two-year funded course in NHS specialist settings, partly because of this, and partly because evidence beyond that window was limited at the time of appraisal. Private treatment timelines are a clinical conversation, not a fixed rule.

Step 2: what happens in the months after stopping

The regain is not instant, but it is faster than many people expect. Trial data from the STEP extension suggest weight begins to climb within the first few weeks of stopping and accelerates through months three to nine before levelling off somewhat. The pattern is gradual enough that it can be mistaken for normal fluctuation early on, which is one reason people are sometimes surprised by where they are a year later.

A few things influence the rate. People who made durable changes to their eating patterns during treatment (higher protein intake, reduced ultra-processed food, more regular meals) tend to fare somewhat better, though this does not prevent regain entirely. Physical activity built during treatment has a similar partial protective effect. Starting weight, how much was lost, and individual metabolic factors also play a role. None of these variables are fully predictable, which is why a prescriber's involvement before and after stopping is genuinely useful rather than just a formality. If you are thinking through what happened after your own course, what to expect after stopping Wegovy covers the timeline in more detail.

One thing the evidence does not support is the idea that stopping abruptly versus tapering makes a meaningful difference to long-term outcomes, the biology responds to the absence of the medicine rather than the speed of removal. Your prescriber, not a general article, is the right source of guidance on how to stop if that is the decision you have reached.

Step 3: the role of continued or restarted treatment

Given how the biology works, it follows that many people who respond well to Wegovy and then stop find themselves considering restarting. This is not a sign of dependency in any clinical sense, it is analogous to restarting blood pressure medication after a period off it. Clinical guidance supports reassessment and, where appropriate, restarting treatment.

Some people move from Wegovy to a broader look at semaglutide options or explore whether a different licensed medicine might suit their circumstances better. Tirzepatide (Mounjaro), for instance, acts on two receptor pathways rather than one and has shown greater average weight loss in head-to-head trial data. Whether switching is clinically appropriate depends on individual history, response and any coexisting conditions, not on trial headlines alone. You can read more about the range of licensed weight-loss treatments and what differentiates them.

For context on what private treatment costs and what is included in the price, Wegovy pricing in the UK sets out the current picture honestly. The question of cost is separate from the question of suitability, and it is worth understanding both before making any decision. Our prescribers at nume's clinical team (sorry, at nume's clinical team) review every consultation personally, including transfers from existing treatment and requests to restart after a gap.

Step 4: reducing regain risk while on treatment

The most useful thing treatment time can be used for is building habits that have some resilience of their own. This is not about compensating for the medicine's absence, it is about making the most of a period when appetite is lower and behaviour change is genuinely easier. Protein intake matters because it preserves muscle mass during weight loss; muscle is metabolically active and supports weight maintenance long after the scales have stopped moving. Resistance training has a similar effect. Both are worth building during treatment, not after it.

None of this is a guarantee. The clinical evidence is clear that lifestyle changes alone do not replicate what the medicine achieves, and combining them does not fully prevent regain on stopping. But they do affect where you land. A prescriber or dietitian can help you think through what is realistic given your particular circumstances, rather than applying a generic plan. If you have specific questions about the process of stopping or what to monitor, our FAQs cover common queries, and you can always reach our team directly.